Global mRNA Cancer Vaccines and Therapeutics Supply, Demand and Key Producers, 2026-2032
The global mRNA Cancer Vaccines and Therapeutics market size is expected to reach $ 11780 million by 2032, rising at a market growth of 4.9% CAGR during the forecast period (2026-2032).
mRNA cancer vaccines and therapeutics are a novel class of tumor immunotherapy products based on messenger RNA (mRNA) technology. This approach involves designing and delivering mRNA molecules encoding tumor-associated antigens, enabling the patient’s immune system to recognize and attack cancer cells, thereby achieving precise and effective anti-cancer responses. Compared to traditional cancer treatments, mRNA technology offers advantages such as shorter development cycles, flexible manufacturing, and strong potential for personalized customization, significantly enhancing treatment safety and efficacy. With rapid advances in biopharmaceuticals and gene editing technologies, mRNA cancer vaccines and therapeutics have emerged as a critical breakthrough in tumor immunotherapy, ushering cancer treatment into the era of precision immunotherapy.
The rising global cancer incidence and mortality rates drive urgent demand for innovative therapies to improve treatment outcomes and patient survival. Leading biopharmaceutical companies’ annual reports highlight sustained investments in mRNA technology platforms, accelerating R&D of cancer vaccines and therapeutics while ensuring safety and efficacy. Government support through policies and funding fosters faster clinical trials and market access. The flexibility and personalization capabilities of mRNA technology meet diverse needs across cancer types and patient populations, showing great potential especially in hard-to-treat and recurrent cancers. Global aging populations and the spread of precision medicine concepts further fuel rapid market growth.
Despite vast market potential, challenges remain. Complex and costly R&D processes with extended validation periods increase development risks. Regulatory environments are evolving, with divergent approval standards and pathways across countries complicating international commercialization. High R&D and manufacturing costs contribute to expensive therapies, limiting patient access in some regions. Intense competition and complex interplay between traditional and emerging immunotherapies require companies to continuously innovate to sustain competitive advantage.
Downstream demand for mRNA cancer vaccines and therapeutics is moving toward diversification and precision. Major comprehensive hospitals and oncology centers prioritize efficacy, safety, and personalized treatment regimens. Patient and market demand for innovative and effective therapies drives growth in personalized mRNA vaccine customization services, fostering a precision medicine ecosystem. Advances in companion diagnostics and data-driven decision-making enable more precise patient stratification and improved clinical outcomes. Accelerated integration of biotech and information technology will expand mRNA cancer therapies to broader cancer types and more complex treatment scenarios.
This report studies the global mRNA Cancer Vaccines and Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for mRNA Cancer Vaccines and Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of mRNA Cancer Vaccines and Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global mRNA Cancer Vaccines and Therapeutics total market, 2021-2032, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: mRNA Cancer Vaccines and Therapeutics total market, key domestic companies, and share, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global mRNA Cancer Vaccines and Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Moderna Therapeutics, Pfizer, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world mRNA Cancer Vaccines and Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global mRNA Cancer Vaccines and Therapeutics Market, By Region:
1. How big is the global mRNA Cancer Vaccines and Therapeutics market?
2. What is the demand of the global mRNA Cancer Vaccines and Therapeutics market?
3. What is the year over year growth of the global mRNA Cancer Vaccines and Therapeutics market?
4. What is the total value of the global mRNA Cancer Vaccines and Therapeutics market?
5. Who are the Major Players in the global mRNA Cancer Vaccines and Therapeutics market?
6. What are the growth factors driving the market demand?
mRNA cancer vaccines and therapeutics are a novel class of tumor immunotherapy products based on messenger RNA (mRNA) technology. This approach involves designing and delivering mRNA molecules encoding tumor-associated antigens, enabling the patient’s immune system to recognize and attack cancer cells, thereby achieving precise and effective anti-cancer responses. Compared to traditional cancer treatments, mRNA technology offers advantages such as shorter development cycles, flexible manufacturing, and strong potential for personalized customization, significantly enhancing treatment safety and efficacy. With rapid advances in biopharmaceuticals and gene editing technologies, mRNA cancer vaccines and therapeutics have emerged as a critical breakthrough in tumor immunotherapy, ushering cancer treatment into the era of precision immunotherapy.
The rising global cancer incidence and mortality rates drive urgent demand for innovative therapies to improve treatment outcomes and patient survival. Leading biopharmaceutical companies’ annual reports highlight sustained investments in mRNA technology platforms, accelerating R&D of cancer vaccines and therapeutics while ensuring safety and efficacy. Government support through policies and funding fosters faster clinical trials and market access. The flexibility and personalization capabilities of mRNA technology meet diverse needs across cancer types and patient populations, showing great potential especially in hard-to-treat and recurrent cancers. Global aging populations and the spread of precision medicine concepts further fuel rapid market growth.
Despite vast market potential, challenges remain. Complex and costly R&D processes with extended validation periods increase development risks. Regulatory environments are evolving, with divergent approval standards and pathways across countries complicating international commercialization. High R&D and manufacturing costs contribute to expensive therapies, limiting patient access in some regions. Intense competition and complex interplay between traditional and emerging immunotherapies require companies to continuously innovate to sustain competitive advantage.
Downstream demand for mRNA cancer vaccines and therapeutics is moving toward diversification and precision. Major comprehensive hospitals and oncology centers prioritize efficacy, safety, and personalized treatment regimens. Patient and market demand for innovative and effective therapies drives growth in personalized mRNA vaccine customization services, fostering a precision medicine ecosystem. Advances in companion diagnostics and data-driven decision-making enable more precise patient stratification and improved clinical outcomes. Accelerated integration of biotech and information technology will expand mRNA cancer therapies to broader cancer types and more complex treatment scenarios.
This report studies the global mRNA Cancer Vaccines and Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for mRNA Cancer Vaccines and Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of mRNA Cancer Vaccines and Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global mRNA Cancer Vaccines and Therapeutics total market, 2021-2032, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: mRNA Cancer Vaccines and Therapeutics total market, key domestic companies, and share, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global mRNA Cancer Vaccines and Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global mRNA Cancer Vaccines and Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Moderna Therapeutics, Pfizer, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world mRNA Cancer Vaccines and Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global mRNA Cancer Vaccines and Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Adeno Carcinomas
- Mucinous Carcinomas
- Adenosquamous Carcinomas
- Infectious Disease
- Cancer
- Others
- Moderna Therapeutics
- Pfizer
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
1. How big is the global mRNA Cancer Vaccines and Therapeutics market?
2. What is the demand of the global mRNA Cancer Vaccines and Therapeutics market?
3. What is the year over year growth of the global mRNA Cancer Vaccines and Therapeutics market?
4. What is the total value of the global mRNA Cancer Vaccines and Therapeutics market?
5. Who are the Major Players in the global mRNA Cancer Vaccines and Therapeutics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 mRNA Cancer Vaccines and Therapeutics Introduction
1.2 World mRNA Cancer Vaccines and Therapeutics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World mRNA Cancer Vaccines and Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.3 China Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.4 Europe Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.5 Japan Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.6 South Korea Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.7 ASEAN Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.8 India Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 mRNA Cancer Vaccines and Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.2 World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region
2.2.1 World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region (2021-2026)
2.2.2 World mRNA Cancer Vaccines and Therapeutics Consumption Value Forecast by Region (2027-2032)
2.3 United States mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.4 China mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.5 Europe mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.6 Japan mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.7 South Korea mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.8 ASEAN mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.9 India mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
3 WORLD MRNA CANCER VACCINES AND THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World mRNA Cancer Vaccines and Therapeutics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global mRNA Cancer Vaccines and Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for mRNA Cancer Vaccines and Therapeutics in 2025
3.2.3 Global Concentration Ratios (CR8) for mRNA Cancer Vaccines and Therapeutics in 2025
3.3 mRNA Cancer Vaccines and Therapeutics Company Evaluation Quadrant
3.4 mRNA Cancer Vaccines and Therapeutics Market: Overall Company Footprint Analysis
3.4.1 mRNA Cancer Vaccines and Therapeutics Market: Region Footprint
3.4.2 mRNA Cancer Vaccines and Therapeutics Market: Company Product Type Footprint
3.4.3 mRNA Cancer Vaccines and Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison
4.2.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based mRNA Cancer Vaccines and Therapeutics Companies and Market Share, 2021-2026
4.3.1 United States Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026)
4.4 China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue and Market Share, 2021-2026
4.4.1 China Based mRNA Cancer Vaccines and Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026)
4.5 Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World mRNA Cancer Vaccines and Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Adeno Carcinomas
5.2.2 Mucinous Carcinomas
5.2.3 Adenosquamous Carcinomas
5.3 Market Segment by Type
5.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
5.3.2 World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
5.3.3 World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World mRNA Cancer Vaccines and Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Infectious Disease
6.2.2 Cancer
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
6.3.2 World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
6.3.3 World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Moderna Therapeutics
7.1.1 Moderna Therapeutics Details
7.1.2 Moderna Therapeutics Major Business
7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Moderna Therapeutics Recent Developments/Updates
7.1.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.2 Pfizer
7.2.1 Pfizer Details
7.2.2 Pfizer Major Business
7.2.3 Pfizer mRNA Cancer Vaccines and Therapeutics Product and Services
7.2.4 Pfizer mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Pfizer Recent Developments/Updates
7.2.6 Pfizer Competitive Strengths & Weaknesses
7.3 Translate Bio
7.3.1 Translate Bio Details
7.3.2 Translate Bio Major Business
7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Services
7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Translate Bio Recent Developments/Updates
7.3.6 Translate Bio Competitive Strengths & Weaknesses
7.4 BioNTech
7.4.1 BioNTech Details
7.4.2 BioNTech Major Business
7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Product and Services
7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 BioNTech Recent Developments/Updates
7.4.6 BioNTech Competitive Strengths & Weaknesses
7.5 Sangamo Therapeutics
7.5.1 Sangamo Therapeutics Details
7.5.2 Sangamo Therapeutics Major Business
7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Sangamo Therapeutics Recent Developments/Updates
7.5.6 Sangamo Therapeutics Competitive Strengths & Weaknesses
7.6 Argos Therapeutics
7.6.1 Argos Therapeutics Details
7.6.2 Argos Therapeutics Major Business
7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Argos Therapeutics Recent Developments/Updates
7.6.6 Argos Therapeutics Competitive Strengths & Weaknesses
7.7 In-Cell-Art
7.7.1 In-Cell-Art Details
7.7.2 In-Cell-Art Major Business
7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Services
7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 In-Cell-Art Recent Developments/Updates
7.7.6 In-Cell-Art Competitive Strengths & Weaknesses
7.8 eTheRNA
7.8.1 eTheRNA Details
7.8.2 eTheRNA Major Business
7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Services
7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 eTheRNA Recent Developments/Updates
7.8.6 eTheRNA Competitive Strengths & Weaknesses
7.9 Ethris
7.9.1 Ethris Details
7.9.2 Ethris Major Business
7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Product and Services
7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Ethris Recent Developments/Updates
7.9.6 Ethris Competitive Strengths & Weaknesses
7.10 Tiba Biotechnology
7.10.1 Tiba Biotechnology Details
7.10.2 Tiba Biotechnology Major Business
7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Services
7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 Tiba Biotechnology Recent Developments/Updates
7.10.6 Tiba Biotechnology Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 mRNA Cancer Vaccines and Therapeutics Industry Chain
8.2 mRNA Cancer Vaccines and Therapeutics Upstream Analysis
8.3 mRNA Cancer Vaccines and Therapeutics Midstream Analysis
8.4 mRNA Cancer Vaccines and Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 mRNA Cancer Vaccines and Therapeutics Introduction
1.2 World mRNA Cancer Vaccines and Therapeutics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World mRNA Cancer Vaccines and Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.3 China Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.4 Europe Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.5 Japan Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.6 South Korea Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.7 ASEAN Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.3.8 India Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 mRNA Cancer Vaccines and Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.2 World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region
2.2.1 World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region (2021-2026)
2.2.2 World mRNA Cancer Vaccines and Therapeutics Consumption Value Forecast by Region (2027-2032)
2.3 United States mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.4 China mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.5 Europe mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.6 Japan mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.7 South Korea mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.8 ASEAN mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
2.9 India mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032)
3 WORLD MRNA CANCER VACCINES AND THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World mRNA Cancer Vaccines and Therapeutics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global mRNA Cancer Vaccines and Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for mRNA Cancer Vaccines and Therapeutics in 2025
3.2.3 Global Concentration Ratios (CR8) for mRNA Cancer Vaccines and Therapeutics in 2025
3.3 mRNA Cancer Vaccines and Therapeutics Company Evaluation Quadrant
3.4 mRNA Cancer Vaccines and Therapeutics Market: Overall Company Footprint Analysis
3.4.1 mRNA Cancer Vaccines and Therapeutics Market: Region Footprint
3.4.2 mRNA Cancer Vaccines and Therapeutics Market: Company Product Type Footprint
3.4.3 mRNA Cancer Vaccines and Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison
4.2.1 United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based mRNA Cancer Vaccines and Therapeutics Companies and Market Share, 2021-2026
4.3.1 United States Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026)
4.4 China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue and Market Share, 2021-2026
4.4.1 China Based mRNA Cancer Vaccines and Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026)
4.5 Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World mRNA Cancer Vaccines and Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Adeno Carcinomas
5.2.2 Mucinous Carcinomas
5.2.3 Adenosquamous Carcinomas
5.3 Market Segment by Type
5.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
5.3.2 World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
5.3.3 World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World mRNA Cancer Vaccines and Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Infectious Disease
6.2.2 Cancer
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
6.3.2 World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
6.3.3 World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Moderna Therapeutics
7.1.1 Moderna Therapeutics Details
7.1.2 Moderna Therapeutics Major Business
7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Moderna Therapeutics Recent Developments/Updates
7.1.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.2 Pfizer
7.2.1 Pfizer Details
7.2.2 Pfizer Major Business
7.2.3 Pfizer mRNA Cancer Vaccines and Therapeutics Product and Services
7.2.4 Pfizer mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Pfizer Recent Developments/Updates
7.2.6 Pfizer Competitive Strengths & Weaknesses
7.3 Translate Bio
7.3.1 Translate Bio Details
7.3.2 Translate Bio Major Business
7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Services
7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Translate Bio Recent Developments/Updates
7.3.6 Translate Bio Competitive Strengths & Weaknesses
7.4 BioNTech
7.4.1 BioNTech Details
7.4.2 BioNTech Major Business
7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Product and Services
7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 BioNTech Recent Developments/Updates
7.4.6 BioNTech Competitive Strengths & Weaknesses
7.5 Sangamo Therapeutics
7.5.1 Sangamo Therapeutics Details
7.5.2 Sangamo Therapeutics Major Business
7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Sangamo Therapeutics Recent Developments/Updates
7.5.6 Sangamo Therapeutics Competitive Strengths & Weaknesses
7.6 Argos Therapeutics
7.6.1 Argos Therapeutics Details
7.6.2 Argos Therapeutics Major Business
7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Argos Therapeutics Recent Developments/Updates
7.6.6 Argos Therapeutics Competitive Strengths & Weaknesses
7.7 In-Cell-Art
7.7.1 In-Cell-Art Details
7.7.2 In-Cell-Art Major Business
7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Services
7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 In-Cell-Art Recent Developments/Updates
7.7.6 In-Cell-Art Competitive Strengths & Weaknesses
7.8 eTheRNA
7.8.1 eTheRNA Details
7.8.2 eTheRNA Major Business
7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Services
7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 eTheRNA Recent Developments/Updates
7.8.6 eTheRNA Competitive Strengths & Weaknesses
7.9 Ethris
7.9.1 Ethris Details
7.9.2 Ethris Major Business
7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Product and Services
7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Ethris Recent Developments/Updates
7.9.6 Ethris Competitive Strengths & Weaknesses
7.10 Tiba Biotechnology
7.10.1 Tiba Biotechnology Details
7.10.2 Tiba Biotechnology Major Business
7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Services
7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 Tiba Biotechnology Recent Developments/Updates
7.10.6 Tiba Biotechnology Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 mRNA Cancer Vaccines and Therapeutics Industry Chain
8.2 mRNA Cancer Vaccines and Therapeutics Upstream Analysis
8.3 mRNA Cancer Vaccines and Therapeutics Midstream Analysis
8.4 mRNA Cancer Vaccines and Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World mRNA Cancer Vaccines and Therapeutics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World mRNA Cancer Vaccines and Therapeutics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World mRNA Cancer Vaccines and Therapeutics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key mRNA Cancer Vaccines and Therapeutics Players in 2025
Table 12. World mRNA Cancer Vaccines and Therapeutics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global mRNA Cancer Vaccines and Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key mRNA Cancer Vaccines and Therapeutics Players
Table 15. mRNA Cancer Vaccines and Therapeutics Market: Company Product Type Footprint
Table 16. mRNA Cancer Vaccines and Therapeutics Market: Company Product Application Footprint
Table 17. mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China mRNA Cancer Vaccines and Therapeutics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 23. China Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 26. Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 29. World mRNA Cancer Vaccines and Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World mRNA Cancer Vaccines and Therapeutics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032) & (USD Million)
Table 32. World mRNA Cancer Vaccines and Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026) & (USD Million)
Table 34. World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032) & (USD Million)
Table 35. Moderna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Moderna Therapeutics Major Business
Table 37. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 38. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Moderna Therapeutics Recent Developments/Updates
Table 40. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 41. Pfizer Basic Information, Manufacturing Base and Competitors
Table 42. Pfizer Major Business
Table 43. Pfizer mRNA Cancer Vaccines and Therapeutics Product and Services
Table 44. Pfizer mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Pfizer Recent Developments/Updates
Table 46. Pfizer Competitive Strengths & Weaknesses
Table 47. Translate Bio Basic Information, Manufacturing Base and Competitors
Table 48. Translate Bio Major Business
Table 49. Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Services
Table 50. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Translate Bio Recent Developments/Updates
Table 52. Translate Bio Competitive Strengths & Weaknesses
Table 53. BioNTech Basic Information, Manufacturing Base and Competitors
Table 54. BioNTech Major Business
Table 55. BioNTech mRNA Cancer Vaccines and Therapeutics Product and Services
Table 56. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. BioNTech Recent Developments/Updates
Table 58. BioNTech Competitive Strengths & Weaknesses
Table 59. Sangamo Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Sangamo Therapeutics Major Business
Table 61. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 62. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Sangamo Therapeutics Recent Developments/Updates
Table 64. Sangamo Therapeutics Competitive Strengths & Weaknesses
Table 65. Argos Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. Argos Therapeutics Major Business
Table 67. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 68. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Argos Therapeutics Recent Developments/Updates
Table 70. Argos Therapeutics Competitive Strengths & Weaknesses
Table 71. In-Cell-Art Basic Information, Manufacturing Base and Competitors
Table 72. In-Cell-Art Major Business
Table 73. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Services
Table 74. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. In-Cell-Art Recent Developments/Updates
Table 76. In-Cell-Art Competitive Strengths & Weaknesses
Table 77. eTheRNA Basic Information, Manufacturing Base and Competitors
Table 78. eTheRNA Major Business
Table 79. eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Services
Table 80. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. eTheRNA Recent Developments/Updates
Table 82. eTheRNA Competitive Strengths & Weaknesses
Table 83. Ethris Basic Information, Manufacturing Base and Competitors
Table 84. Ethris Major Business
Table 85. Ethris mRNA Cancer Vaccines and Therapeutics Product and Services
Table 86. Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Ethris Recent Developments/Updates
Table 88. Ethris Competitive Strengths & Weaknesses
Table 89. Tiba Biotechnology Basic Information, Manufacturing Base and Competitors
Table 90. Tiba Biotechnology Major Business
Table 91. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Services
Table 92. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Tiba Biotechnology Recent Developments/Updates
Table 94. Tiba Biotechnology Competitive Strengths & Weaknesses
Table 95. Global Key Players of mRNA Cancer Vaccines and Therapeutics Upstream (Raw Materials)
Table 96. Global mRNA Cancer Vaccines and Therapeutics Typical Customers
Table 1. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World mRNA Cancer Vaccines and Therapeutics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World mRNA Cancer Vaccines and Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World mRNA Cancer Vaccines and Therapeutics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World mRNA Cancer Vaccines and Therapeutics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key mRNA Cancer Vaccines and Therapeutics Players in 2025
Table 12. World mRNA Cancer Vaccines and Therapeutics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global mRNA Cancer Vaccines and Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key mRNA Cancer Vaccines and Therapeutics Players
Table 15. mRNA Cancer Vaccines and Therapeutics Market: Company Product Type Footprint
Table 16. mRNA Cancer Vaccines and Therapeutics Market: Company Product Application Footprint
Table 17. mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China mRNA Cancer Vaccines and Therapeutics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China mRNA Cancer Vaccines and Therapeutics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 23. China Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 26. Rest of World Based mRNA Cancer Vaccines and Therapeutics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies mRNA Cancer Vaccines and Therapeutics Revenue Market Share (2021-2026)
Table 29. World mRNA Cancer Vaccines and Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World mRNA Cancer Vaccines and Therapeutics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032) & (USD Million)
Table 32. World mRNA Cancer Vaccines and Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026) & (USD Million)
Table 34. World mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032) & (USD Million)
Table 35. Moderna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Moderna Therapeutics Major Business
Table 37. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 38. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Moderna Therapeutics Recent Developments/Updates
Table 40. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 41. Pfizer Basic Information, Manufacturing Base and Competitors
Table 42. Pfizer Major Business
Table 43. Pfizer mRNA Cancer Vaccines and Therapeutics Product and Services
Table 44. Pfizer mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Pfizer Recent Developments/Updates
Table 46. Pfizer Competitive Strengths & Weaknesses
Table 47. Translate Bio Basic Information, Manufacturing Base and Competitors
Table 48. Translate Bio Major Business
Table 49. Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Services
Table 50. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Translate Bio Recent Developments/Updates
Table 52. Translate Bio Competitive Strengths & Weaknesses
Table 53. BioNTech Basic Information, Manufacturing Base and Competitors
Table 54. BioNTech Major Business
Table 55. BioNTech mRNA Cancer Vaccines and Therapeutics Product and Services
Table 56. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. BioNTech Recent Developments/Updates
Table 58. BioNTech Competitive Strengths & Weaknesses
Table 59. Sangamo Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Sangamo Therapeutics Major Business
Table 61. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 62. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Sangamo Therapeutics Recent Developments/Updates
Table 64. Sangamo Therapeutics Competitive Strengths & Weaknesses
Table 65. Argos Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. Argos Therapeutics Major Business
Table 67. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Services
Table 68. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Argos Therapeutics Recent Developments/Updates
Table 70. Argos Therapeutics Competitive Strengths & Weaknesses
Table 71. In-Cell-Art Basic Information, Manufacturing Base and Competitors
Table 72. In-Cell-Art Major Business
Table 73. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Services
Table 74. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. In-Cell-Art Recent Developments/Updates
Table 76. In-Cell-Art Competitive Strengths & Weaknesses
Table 77. eTheRNA Basic Information, Manufacturing Base and Competitors
Table 78. eTheRNA Major Business
Table 79. eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Services
Table 80. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. eTheRNA Recent Developments/Updates
Table 82. eTheRNA Competitive Strengths & Weaknesses
Table 83. Ethris Basic Information, Manufacturing Base and Competitors
Table 84. Ethris Major Business
Table 85. Ethris mRNA Cancer Vaccines and Therapeutics Product and Services
Table 86. Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Ethris Recent Developments/Updates
Table 88. Ethris Competitive Strengths & Weaknesses
Table 89. Tiba Biotechnology Basic Information, Manufacturing Base and Competitors
Table 90. Tiba Biotechnology Major Business
Table 91. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Services
Table 92. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Tiba Biotechnology Recent Developments/Updates
Table 94. Tiba Biotechnology Competitive Strengths & Weaknesses
Table 95. Global Key Players of mRNA Cancer Vaccines and Therapeutics Upstream (Raw Materials)
Table 96. Global mRNA Cancer Vaccines and Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. mRNA Cancer Vaccines and Therapeutics Picture
Figure 2. World mRNA Cancer Vaccines and Therapeutics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World mRNA Cancer Vaccines and Therapeutics Total Revenue (2021-2032) & (USD Million)
Figure 4. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 13. mRNA Cancer Vaccines and Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 16. World mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 18. China mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. India mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of mRNA Cancer Vaccines and Therapeutics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for mRNA Cancer Vaccines and Therapeutics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for mRNA Cancer Vaccines and Therapeutics Markets in 2025
Figure 27. United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World mRNA Cancer Vaccines and Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type in 2025
Figure 31. Adeno Carcinomas
Figure 32. Mucinous Carcinomas
Figure 33. Adenosquamous Carcinomas
Figure 34. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type (2021-2032)
Figure 35. World mRNA Cancer Vaccines and Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 36. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application in 2025
Figure 37. Infectious Disease
Figure 38. Cancer
Figure 39. Others
Figure 40. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application (2021-2032)
Figure 41. mRNA Cancer Vaccines and Therapeutics Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
Figure 1. mRNA Cancer Vaccines and Therapeutics Picture
Figure 2. World mRNA Cancer Vaccines and Therapeutics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World mRNA Cancer Vaccines and Therapeutics Total Revenue (2021-2032) & (USD Million)
Figure 4. World mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032) & (USD Million)
Figure 13. mRNA Cancer Vaccines and Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 16. World mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 18. China mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. India mRNA Cancer Vaccines and Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of mRNA Cancer Vaccines and Therapeutics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for mRNA Cancer Vaccines and Therapeutics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for mRNA Cancer Vaccines and Therapeutics Markets in 2025
Figure 27. United States VS China: mRNA Cancer Vaccines and Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: mRNA Cancer Vaccines and Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World mRNA Cancer Vaccines and Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type in 2025
Figure 31. Adeno Carcinomas
Figure 32. Mucinous Carcinomas
Figure 33. Adenosquamous Carcinomas
Figure 34. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Type (2021-2032)
Figure 35. World mRNA Cancer Vaccines and Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 36. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application in 2025
Figure 37. Infectious Disease
Figure 38. Cancer
Figure 39. Others
Figure 40. World mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Application (2021-2032)
Figure 41. mRNA Cancer Vaccines and Therapeutics Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
